| Literature DB >> 29385194 |
Daniela Schmid1, Gundula Behrens1, Hannah Arem2, Christina Hart3, Wolfgang Herr3, Carmen Jochem1, Charles E Matthews4, Michael F Leitzmann1.
Abstract
PURPOSE: The associations of physical activity and television (TV) viewing with mortality risk among individuals with hematologic malignancies remain unclear.Entities:
Mesh:
Year: 2018 PMID: 29385194 PMCID: PMC5791989 DOI: 10.1371/journal.pone.0192078
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the study participants diagnosed with incident hematologic cancer according to pre-diagnosis physical activity and TV viewing.
| Characteristics | Pre-diagnosis physical activity | Pre-diagnosis TV viewing | |||||
|---|---|---|---|---|---|---|---|
| <1 hr/wk | 1 to 3 hrs/wk | ≥4 hrs/week | 0 to 2 hrs/d | 3 to 4 hrs/d | ≥5 hrs/d | ||
| Number of participants | 1278 | 1272 | 2585 | 1750 | 2394 | 1038 | |
| Hematologic cancer subtype, % | |||||||
| Hodgkin lymphoma | 1.8 | 1.9 | 2.4 | 2.0 | 2.0 | 2.6 | |
| Non-Hodgkin lymphoma | 49.4 | 52.9 | 49.7 | 53.5 | 49.4 | 47.4 | |
| Myeloma | 16.3 | 15.7 | 16.8 | 16.0 | 16.3 | 17.0 | |
| Leukemia | 32.4 | 29.5 | 31.1 | 28.6 | 32.2 | 33.0 | |
| Age at exposure assessment, years, mean (SD) | 63.5 (5.1) | 63.7 (5.0) | 64.3 (4.8) | 63.3 (5.2) | 64.1 (4.8) | 64.6 (4.7) | |
| Age at diagnosis, years, mean (SD) | 71.0 (6.4) | 71.3 (6.4) | 72.0 (6.1) | 71.1 (6.5) | 71.8 (6.2) | 71.9 (6.1) | |
| Sex, % | |||||||
| Men | 66.9 | 68.2 | 69.0 | 68.6 | 68.5 | 66.1 | |
| Women | 33.1 | 31.8 | 31.0 | 31.4 | 31.5 | 33.9 | |
| Non-Hispanic White, % | 92.8 | 94.3 | 94.4 | 95.2 | 94.4 | 90.9 | |
| Pre-diagnosis smoking status, % | |||||||
| Never smoker | 34.7 | 35.0 | 36.7 | 42.9 | 32.0 | 32.2 | |
| Past smoker | 49.5 | 52.9 | 52.5 | 47.5 | 54.9 | 51.9 | |
| Current smoker | 11.8 | 9.7 | 7.8 | 6.7 | 10.0 | 12.3 | |
| College graduate/post graduate, % | 41.0 | 43.2 | 44.3 | 56.7 | 39.6 | 27.4 | |
| Pre-diagnosis body mass index, kg/m2, mean (SD) | 28.6 (5.3) | 27.5 (4.6) | 26.6 (3.9) | 26.4 (4.0) | 27.5 (4.5) | 28.6 (5.2) | |
| Pre-diagnosis alcohol intake, % | |||||||
| 0 g/d | 28.0 | 21.8 | 21.4 | 23.1 | 22.0 | 26.0 | |
| >0 to 14.9 g/d | 54.0 | 57.7 | 55.4 | 55.3 | 55.5 | 56.5 | |
| ≥15 g/d | 18.0 | 20.6 | 23.1 | 21.6 | 22.5 | 17.5 | |
| Chemotherapy (first course of treatment), % | 28.6 | 26.7 | 29.0 | 29.3 | 28.0 | 27.9 | |
| Pre-diagnosis self-reported heath status, % | |||||||
| Excellent/very good | 40.5 | 49.6 | 62.2 | 62.9 | 52.5 | 39.8 | |
| Good | 40.2 | 39.9 | 30.0 | 29.5 | 36.1 | 40.9 | |
| Fair/poor | 17.3 | 8.9 | 6.6 | 6.3 | 9.8 | 17.7 | |
All values (except age) are standardized to the age distribution of the study population. Categories may not sum up to 100% due to missing data. Smoking status, body mass index, alcohol intake, and self-reported health status were assessed in the baseline questionnaire.
HRs and 95% CI of mortality among individuals diagnosed with hematologic cancer according to physical activity before and after diagnosis.
| Pre-diagnosis physical activity | Post-diagnosis physical activity | |||||||
|---|---|---|---|---|---|---|---|---|
| <1 hr/wk | 1 to 3 hrs/wk | ≥4 hrs/wk | <1 hr/wk | 1 to <4 hrs/wk | ≥4 hrs/wk | |||
| Person-years | 5121 | 5749 | 11637 | 2460 | 3595 | 4001 | ||
| Deaths | 701 | 623 | 1261 | 206 | 216 | 191 | ||
| Model 1 | 1.00 | 0.81 (0.73–0.90) | 0.78 (0.71–0.86) | <0.001 | 1.00 | 0.72 (0.59–0.87) | 0.56 (0.46–0.68) | <0.001 |
| Model 2 | 1.00 | 0.85 (0.76–0.95) | 0.82 (0.74–0.90) | <0.001 | 1.00 | 0.76 (0.63–0.93) | 0.61 (0.50–0.74) | <0.001 |
| Model 3 | 1.00 | 0.87 (0.78–0.97) | 0.85 (0.77–0.93) | 0.005 | 1.00 | 0.77 (0.63–0.94) | 0.61 (0.50–0.75) | <0.001 |
| Deaths | 485 | 407 | 891 | 95 | 122 | 110 | ||
| Model 1 | 1.00 | 0.77 (0.68–0.88) | 0.82 (0.73–0.91) | 0.02 | 1.00 | 0.87 (0.67–1.14) | 0.69 (0.52–0.91) | 0.01 |
| Model 2 | 1.00 | 0.81 (0.71–0.92) | 0.84 (0.75–0.94) | 0.03 | 1.00 | 0.95 (0.72–1.25) | 0.79 (0.59–1.05) | 0.08 |
| Model 3 | 1.00 | 0.83 (0.72–0.94) | 0.87 (0.77–0.97) | 0.12 | 1.00 | 0.95 (0.72–1.25) | 0.79 (0.59–1.06) | 0.09 |
| Deaths | 295 | 281 | 523 | 85 | 110 | 90 | ||
| Model 1 | 1.00 | 0.84 (0.72–0.99) | 0.77 (0.67–0.89) | 0.001 | 1.00 | 0.88 (0.66–1.17) | 0.62 (0.46–0.84) | 0.001 |
| Model 2 | 1.00 | 0.89 (0.75–1.05) | 0.82 (0.71–0.95) | 0.01 | 1.00 | 0.91 (0.68–1.22) | 0.63 (0.47–0.86) | 0.002 |
| Model 3 | 1.00 | 0.90 (0.77–1.07) | 0.85 (0.73–0.99) | 0.03 | 1.00 | 0.93 (0.69–1.24) | 0.64 (0.47–0.87) | 0.003 |
| Deaths | 137 | 119 | 274 | 46 | 41 | 34 | ||
| Model 1 | 1.00 | 0.79 (0.62–1.01) | 0.86 (0.70–1.05) | 0.42 | 1.00 | 0.59 (0.39–0.91) | 0.47 (0.30–0.75) | 0.002 |
| Model 2 | 1.00 | 0.75 (0.58–0.96) | 0.78 (0.63–0.96) | 0.10 | 1.00 | 0.65 (0.40–1.05) | 0.52 (0.31–0.85) | 0.01 |
| Model 3 | 1.00 | 0.76 (0.59–0.98) | 0.81 (0.66–1.01) | 0.24 | 1.00 | 0.66 (0.41–1.06) | 0.53 (0.32–0.88) | 0.02 |
| Deaths | 254 | 211 | 439 | 68 | 61 | 62 | ||
| Model 1 | 1.00 | 0.82 (0.69–0.99) | 0.77 (0.66–0.90) | 0.003 | 1.00 | 0.63 (0.44–0.89) | 0.55 (0.39–0.78) | 0.002 |
| Model 2 | 1.00 | 0.88 (0.73–1.06) | 0.81 (0.69–0.95) | 0.01 | 1.00 | 0.65 (0.45–0.93) | 0.58 (0.40–0.84) | 0.01 |
| Model 3 | 1.00 | 0.91 (0.75–1.09) | 0.84 (0.72–0.99) | 0.048 | 1.00 | 0.65 (0.45–0.94) | 0.56 (0.38–0.83) | 0.01 |
| Deaths | 134 | 97 | 235 | |||||
| Model 1 | 1.00 | 0.81 (0.62–1.05) | 0.83 (0.67–1.03) | 0.20 | - | - | - | - |
| Model 2 | 1.00 | 0.76 (0.58–1.01) | 0.90 (0.72–1.13) | 0.83 | - | - | - | - |
| Model 3 | 1.00 | 0.79 (0.60–1.05) | 0.94 (0.75–1.18) | 0.94 | - | - | - | - |
| Deaths | 105 | 100 | 170 | 57 | 49 | 49 | ||
| Model 1 | 1.00 | 0.91 (0.69–1.20) | 0.65 (0.51–0.83) | <0.001 | 1.00 | 0.66 (0.45–0.97) | 0.54 (0.36–0.79) | 0.003 |
| Model 2 | 1.00 | 0.92 (0.69–1.22) | 0.65 (0.50–0.83) | <0.001 | 1.00 | 0.70 (0.47–1.05) | 0.57 (0.38–0.86) | 0.01 |
| Model 3 | 1.00 | 0.93 (0.70–1.24) | 0.67 (0.51–0.87) | 0.001 | 1.00 | 0.68 (0.45–1.03) | 0.54 (0.35–0.83) | 0.01 |
HR = hazard ratio, CI = confidence interval. Model 1: adjusted for age at exposure assessment (continuous), age at cancer diagnosis (continuous), and sex. Model 2: adjusted for all variables in Model 1 and additionally adjusted for education (less than 12 yrs, 12 yrs, vocational training or some college education, college graduate/postgraduate, unknown), race (non-Hispanic White, non-Hispanic Black, other, unknown), smoking (never smoker, former smoker with 20 cigarettes per day or less, former smoker with more than 20 cigarettes per day, current smoker with 20 cigarettes per day or less, current smoker with more than 20 cigarettes per day, missing), alcohol consumption (0, >0 to 14.9, ≥15g/d), chemotherapy (yes, no, unknown/missing), hematologic cancer subtype (NHL, HL, myeloma, leukemia) and stage in NHL survivors (localized/regional/in situ, systemic disease, unknown/not abstracted/missing), and TV viewing. Model 3: adjusted for all variables in Model 2 and additionally adjusted for body mass index (18.5-<25.0kg/m2, 25.0-<30.0 kg/m2, 30.0-<35.kg/m2, 35-<65 kg/m2).
* Data were not evaluated for post-diagnosis physical activity due to low sample size (n = 23).
HRs and 95% CI of mortality among individuals diagnosed with hematologic cancer according to TV viewing before and after diagnosis.
| Pre-diagnosis TV viewing | Post-diagnosis TV viewing | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 to 2 hrs/d | 3 to 4 hrs/d | ≥5 hrs/d | 0 to 2 hrs/d | >2 to 4 hrs/d | >4 hrs/d | |||
| Person-years | 8127 | 10223 | 4426 | 3560 | 3439 | 2240 | ||
| Deaths | 774 | 1239 | 593 | 201 | 199 | 177 | ||
| Model 1 | 1.00 | 1.20 (1.10–1.32) | 1.30 (1.17–1.45) | <0.001 | 1.00 | 1.00 (0.82–1.22) | 1.41 (1.15–1.72) | 0.003 |
| Model 2 | 1.00 | 1.11 (1.01–1.21) | 1.14 (1.02–1.28) | 0.01 | 1.00 | 0.94 (0.77–1.14) | 1.20 (0.97–1.48) | 0.15 |
| Model 3 | 1.00 | 1.09 (0.99–1.19) | 1.10 (0.99–1.24) | 0.06 | 1.00 | 0.93 (0.77–1.14) | 1.19 (0.96–1.47) | 0.19 |
| Deaths | 553 | 851 | 391 | 109 | 111 | 86 | ||
| Model 1 | 1.00 | 1.16 (1.04–1.29) | 1.21 (1.07–1.38) | 0.002 | 1.00 | 1.05 (0.80–1.36) | 1.29 (0.97–1.72) | 0.10 |
| Model 2 | 1.00 | 1.08 (0.97–1.21) | 1.10 (0.96–1.25) | 0.14 | 1.00 | 0.99 (0.76–1.30) | 1.13 (0.84–1.52) | 0.47 |
| Model 3 | 1.00 | 1.07 (0.96–1.19) | 1.06 (0.93–1.22) | 0.32 | 1.00 | 0.99 (0.76–1.29) | 1.12 (0.83–1.52) | 0.51 |
| Deaths | 337 | 524 | 247 | 100 | 96 | 76 | ||
| Model 1 | 1.00 | 1.27 (1.10–1.45) | 1.39 (1.18–1.64) | <0.001 | 1.00 | 1.03 (0.78–1.37) | 1.30 (0.96–1.75) | 0.12 |
| Model 2 | 1.00 | 1.18 (1.02–1.36) | 1.25 (1.05–1.49) | 0.01 | 1.00 | 1.04 (0.78–1.38) | 1.17 (0.86–1.60) | 0.34 |
| Model 3 | 1.00 | 1.16 (1.01–1.34) | 1.23 (1.03–1.46) | 0.01 | 1.00 | 1.03 (0.78–1.38) | 1.15 (0.84–1.58) | 0.41 |
| Deaths | 173 | 244 | 119 | 41 | 36 | 33 | ||
| Model 1 | 1.00 | 0.90 (0.74–1.10) | 0.86 (0.68–1.09) | 0.19 | 1.00 | 0.87 (0.55–1.36) | 1.08 (0.68–1.73) | 0.84 |
| Model 2 | 1.00 | 0.85 (0.70–1.05) | 0.79 (0.61–1.02) | 0.05 | 1.00 | 0.86 (0.52–1.43) | 0.98 (0.57–1.67) | 0.89 |
| Model 3 | 1.00 | 0.85 (0.69–1.04) | 0.76 (0.59–0.98) | 0.03 | 1.00 | 0.85 (0.51–1.42) | 0.92 (0.53–1.59) | 0.73 |
| Deaths | 253 | 446 | 211 | 55 | 61 | 63 | ||
| Model 1 | 1.00 | 1.19 (1.02–1.39) | 1.28 (1.07–1.54) | 0.01 | 1.00 | 0.99 (0.69–1.43) | 1.65 (1.15–2.37) | 0.01 |
| Model 2 | 1.00 | 1.17 (0.996–1.37) | 1.19 (0.99–1.45) | 0.05 | 1.00 | 0.86 (0.59–1.25) | 1.46 (0.99–2.16) | 0.09 |
| Model 3 | 1.00 | 1.15 (0.98–1.35) | 1.15 (0.95–1.40) | 0.11 | 1.00 | 0.86 (0.59–1.25) | 1.50 (1.003–2.25) | 0.09 |
| Deaths | 135 | 224 | 111 | |||||
| Model 1 | 1.00 | 1.29 (1.04–1.61) | 1.51 (1.18–1.95) | 0.001 | - | - | - | |
| Model 2 | 1.00 | 1.29 (1.03–1.60) | 1.46 (1.13–1.91) | 0.003 | - | - | - | |
| Model 3 | 1.00 | 1.27 (1.01–1.58) | 1.39 (1.06–1.82) | 0.01 | - | - | - | |
| Deaths | 104 | 190 | 82 | 42 | 49 | 54 | ||
| Model 1 | 1.00 | 1.16 (0.91–1.48) | 1.08 (0.81–1.44) | 0.50 | 1.00 | 0.98 (0.65–1.48) | 1.71 (1.14–2.56) | 0.01 |
| Model 2 | 1.00 | 1.16 (0.91–1.49) | 0.99 (0.73–1.34) | 0.89 | 1.00 | 0.84 (0.54–1.29) | 1.57 (1.02–2.42) | 0.06 |
| Model 3 | 1.00 | 1.13 (0.88–1.46) | 0.95 (0.69–1.29) | 0.88 | 1.00 | 0.86 (0.55–1.32) | 1.69 (1.07–2.67) | 0.04 |
HR = hazard ratio, CI = confidence interval, TV = television, BMI = body mass index. Model 1: adjusted for age at exposure assessment (continuous), age at cancer diagnosis (continuous), and sex. Model 2: adjusted for all variables in Model 1 and additionally adjusted for education (less than 12 yrs, 12 yrs, vocational training or some college education, college graduate/postgraduate, unknown), race (non-Hispanic White, non-Hispanic Black, other, unknown), smoking (never smoker, former smoker with 20 cigarettes per day or less, former smoker with more than 20 cigarettes per day, current smoker with 20 cigarettes per day or less, current smoker with more than 20 cigarettes per day, missing), alcohol consumption (0, >0 to 14.9, ≥15g/d), chemotherapy (yes, no, unknown/missing), hematologic cancer subtype (NHL, HL, myeloma, leukemia) and stage in NHL survivors (localized/regional/in situ, systemic disease, unknown/not abstracted/missing), and physical activity. Model 3: adjusted for all variables in Model 2 and additionally adjusted for body mass index (18.5-<25.0kg/m2, 25.0-<30.0 kg/m2, 30.0-<35.kg/m2, 35-<65 kg/m2). Data were not evaluated for post-diagnosis physical activity due to low sample size (n = 23).
*Data were not evaluated for post-diagnosis TV viewing due to low sample size (n = 21)
Joint associations of pre- and post-physical activity and TV viewing with all-cause mortality among survivors of hematologic malignancies.
| TV viewing | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical activity | Pre-diagnosis | |||||||||||||
| All hematologic cancer survivors | NHL survivors | Myeloma survivors | Leukemia survivors | Acute leukemia survivors | Chronic leukemia survivors | |||||||||
| High (≥3 to hrs/d) | Low (0 to 2 hrs/d) | High (≥3 to hrs/d) | Low (0 to 2 hrs/d) | High (≥3 to hrs/d) | Low (≥3 to hrs/d) | High (≥3 to hrs/d) | Low (0 to 2 hrs/d) | High (≥3 to hrs/d) | Low (0 to 2 hrs/d) | High (≥3 to hrs/d) | Low (0 to 2 hrs/d) | |||
| Deaths | 519 | 178 | 209 | 85 | 102 | 34 | 196 | 56 | 103 | 31 | 80 | 23 | ||
| Multivariable-adjusted HR (95% CI) | 1.00 | 0.91 (0.77–1.08) | 1.00 | 0.91 (0.71–1.18) | 1.00 | 1.16 (0.78–1.74) | 1.00 | 0.89 (0.66–1.21) | 1.00 | 0.61 (0.41–0.93) | 1.00 | 0.98 (0.61–1.58) | ||
| Deaths | 1292 | 587 | 552 | 250 | 255 | 137 | 456 | 192 | 230 | 102 | 190 | 78 | ||
| Multivariable-adjusted HR (95% CI) | 0.83 (0.75–0.92) | 0.74 (0.65–0.83) | 0.87 (0.74–1.02) | 0.71 (0.59–0.86) | 0.75 (0.59–0.95) | 0.93 (0.71–1.21) | 0.85 (0.71–1.01) | 0.70 (0.57–0.86) | 0.79 (0.61–1.01) | 0.64 (0.48–0.85) | 0.77 (0.58–1.004) | 0.66 (0.47–0.92) | ||
| Deaths | 140 | 57 | 55 | 29 | 30 | 12 | 50 | 14 | 42 | 12 | ||||
| Multivariable-adjusted HR (95% CI) | 1.00 | 0.83 (0.61–1.13) | 1.00 | 0.83 (0.53–1.31) | 1.00 | 0.76 (0.37–1.59) | 1.00 | 0.85 (0.46–1.60) | - | - | 1.00 | 0.89 (0.45–1.75) | ||
| Deaths | 234 | 142 | 115 | 70 | 39 | 29 | 74 | 40 | 61 | 30 | ||||
| Multivariable-adjusted HR (95% CI) | 0.62 (0.5–0.77) | 0.63 (0.50–0.81) | 0.69 (0.50–0.95) | 0.62 (0.43–0.90) | 0.50 (0.29–0.85) | 0.67 (0.36–1.24) | 0.60 (0.41–0.88) | 0.57 (0.37–0.89) | - | - | 0.66 (0.43–1.01) | 0.62 (0.38–1.02) | ||
HR = hazard ratio, CI = confidence interval, TV = television, BMI = body mass index. Low PA = low physical activity (<1 hr/wk), High PA = high physical activity (≥1 hr/wk), Low TV = low television viewing (<3 hrs/d), High TV = high television viewing (≥3 hrs/d). Multivariable models are adjusted for age at exposure assessment (continuous), age at cancer diagnosis (continuous), education (less than 12 yrs, 12 yrs, vocational training or some college education, college graduate/postgraduate, unknown), race (non-Hispanic White, non-Hispanic Black, other, unknown), smoking (never smoker, former smoker with 20 cigarettes per day or less, former smoker with more than 20 cigarettes per day, current smoker with 20 cigarettes per day or less, current smoker with more than 20 cigarettes per day, missing), alcohol consumption (0, >0 to 14.9, ≥15g/d), hematologic cancer subtype (NHL, HL, myeloma, leukemia) and stage in NHL survivors (localized/regional/in situ, systemic disease, unknown/not abstracted/missing), and chemotherapy (yes, no, unknown/missing).
*Data were not evaluated for the post-diagnosis combination of physical activity and TV viewing due to low sample size.